



# Nicox completes transfer of Commercial Operations to new pan-European Ophthalmic Specialty Pharmaceutical Company led by GHO Capital

.....

August 10, 2016

Sophia Antipolis, France.

**Nicox S.A.** (Euronext Paris: FR0013018124, COX), the international ophthalmic company, today announced the completion of the transfer of its European and International commercial operations and related late-stage development programs to a newly-founded, private, pan-European ophthalmic specialty pharmaceutical company. This transfer includes the affiliates Nicox Pharma (France), together with its Spanish and UK operations, Nicox GmbH (Germany), Laboratoires Nicox (France) and Nicox Farma (Italy), all commercial products and the rights (and associated agreements) to AzaSite®, AzaSite Xtra®, BromSite™ for Europe, Middle East and Africa and NCX 4240 outside of Japan and North America. No other Nicox affiliates, operations or programs are included in or affected by this transaction.

Nicox will receive a €9 million cash payment from GHO Capital as a result of the completion of this transaction. For further information on the transaction, please refer to Nicox's Press Release dated July 5, 2016.

.....

## About Nicox

Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an international R&D company focused on the ophthalmic market. For more information on Nicox, its products or pipeline, please visit: [www.nicox.com](http://www.nicox.com).

.....

## Analyst coverage

Bryan, Garnier & Co  
Invest Securities  
Gilbert Dupont  
Stifel

Hugo Solvet  
Martial Descoutures  
Damien Choplain  
Max Hermann

Paris, France  
Paris, France  
Paris, France  
London, UK



## Upcoming financial and business conferences

September 11-13	Rodman & Renshaw Annual Global Investment Conference	New York, US
October 5-6	Large & Midcap Event	Paris, France
November 15-16	Stifel 2016 Healthcare Conference	New York, US
November 18-19	Actionnaria	Paris, France
November 21-23	Deutsches Eigenkapitalforum	Frankfurt, Germany
December 13	Guggenheim Securities 4th Annual Boston Healthcare Conference	Boston, US

---

## Contacts

**Nicox**                    **Gavin Spencer** | Executive Vice President Corporate Development  
Tel +33 (0)4 97 24 53 00 | [communications@nicox.com](mailto:communications@nicox.com)

### Media Relations

*United Kingdom*                    **Jonathan Birt**  
Tel +44 7860 361 746 | [jonathan.birt@ymail.com](mailto:jonathan.birt@ymail.com)

*France*                    **NewCap** | Nicolas Merigeau  
Tel +33 (0)1 44 71 94 98 | [nicox@newcap.eu](mailto:nicox@newcap.eu)

*United States*                    **Argot Partners** | Eliza Schleifstein  
Tel +1 (917) 763-8106 | [eliza@argotpartners.com](mailto:eliza@argotpartners.com)

### Investor Relations

*Europe*                    **NewCap** | Julien Perez | Valentine Brouchet  
Tel +33 (0)1 44 71 94 94 | [nicox@newcap.eu](mailto:nicox@newcap.eu)

*United States*                    **Argot Partners** | Melissa Forst  
Tel +1 (212) 600-1902 | [melissa@argotpartners.com](mailto:melissa@argotpartners.com)

---

The information contained in this document may be modified without former notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.